Lunai Bioworks Inc.
Financial highlights
| Metric | FY June 30, 2025 | FY June 30, 2024 | FY June 30, 2023 | FY June 30, 2022 | FY June 30, 2021 |
|---|---|---|---|---|---|
| Operating income | -$189.0M | -$81.6M | -$38.6M | -$116.1M | -$23.4M |
| Operating expenses | $189.0M | $81.6M | $38.6M | $116.1M | $23.4M |
| Cash from operations | -$7.9M | -$11.0M | -$11.8M | -$15.7M | -$20.6M |
| Capital expenditure | — | $70,430 | $29,774 | $5,156 | $48,892 |
| Free cash flow | — | -$11.0M | -$11.8M | -$15.7M | -$20.7M |
| Impairments | $0 | $0 | $0 | $93.3M | — |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M |
Shares outstanding 36.3M
Annual filing data through FY ended June 30, 2025; float as of July 2, 2026.